Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week… Read More
Sanofi and Teva Pharmaceuticals have revealed new results from their Phase IIb study of duvakitug for ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease (IBD). The results were shared in two oral presentations at the 20th Congress of the… Read More
Both Teva and Daichi Sankyo have been found to be in breach of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice by the Prescription Medicines Code of Practice Authority (PMCPA). Teva was ruled in breach of several clauses of the 2019 Code for… Read More
